Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Debt (2021)

ARS Pharmaceuticals (SPRY) has disclosed Non-Current Debt for 1 consecutive years, with $4.9 million as the latest value for Q4 2021.

  • Quarterly Non-Current Debt changed N/A to $4.9 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2021, changed N/A year-over-year, with the annual reading at $4.9 million for FY2021, N/A changed from the prior year.
  • Non-Current Debt hit $4.9 million in Q4 2021 for ARS Pharmaceuticals.
  • In the past five years, Non-Current Debt ranged from a high of $4.9 million in Q4 2021 to a low of $4.9 million in Q4 2021.